A Road-to-Market Analysis for Non-Small Cell Lung Cancer Products: Tyrosine Kinase Inhibitors as a case study

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-D-005-Monday
• By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
• Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  Enrico Tognana: European Medicines Agency, EMA, London, United Kingdom
  Francesco Pignatti: European Medicines Agency, EMA, London, United Kingdom
  Corinne De Vries: European Medicines Agency, EMA, London, United Kingdom
  
• Abstract:

  Backgrounds

  Pre- and post- submission factors influence the Road-to-Market for medicinal products.

  Aims

  This work analysed the Road-to-Market for 10 NSCLC-TKIs products for which an MAA had been submitted.

  Methods

  The choice was based on the clinical relevance and potential identification of the most significant factors in the Road-to-Market for

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login